Paul-François Cossa, country chair of Sanofi Czech Republic & Slovakia and General Manager CHC, reviews the outstanding performance of the company in 2019, breaks down his new vision for Sanofi in the Czech Republic and Slovakia after the divestment of Zentiva at the end of 2018, and explains how it ties in with new CEO Paul Hudson’s strategic priorities. Cossa also lays down his strategy to grow above market in the dynamic and mature OTC environment. Finally, Cossa discusses the industry’s efforts to improve the market access and pricing environment for innovative medicines in the country.
As part of the AIFP, Sanofi is very much involved in trying to shape the environment in a way that provides a better frame and visibility for bringing innovation to the Czech market
